Pharmaceutical

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Feb 2, 2024 - 18:00
AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL
AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Read the original article

Tags:

Previous Article

IGC Pharma heads towards a Phase I study for Alzheimer’s disease

Next Article

As England’s virus hospitalisations surge flu vaccines evolve

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA’s Woodcock reflects on more than 30 years at agency — and hints at what’s next

STAT+: FDA’s Woodcock reflects on more than 30 years at...

Jan 30, 2024

Juno Pharmaceuticals buys Omega Laboratories

Juno Pharmaceuticals buys Omega Laboratories

May 16, 2023

Biden launches a new push to limit health care costs, hoping to show he can save money for families

Biden launches a new push to limit health care costs, h...

Jul 8, 2023